A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 26975357)

Published in Pharm Res on March 14, 2016

Authors

Erica Schlesinger1, Daniel Johengen2, Ellen Luecke3, Ginger Rothrock4, Ian McGowan5, Ariane van der Straten3,6, Tejal Desai7,8

Author Affiliations

1: UC Berkeley-UCSF Graduate Program in Bioengineering, 1700 4th Street Room 204, UCSF Mission Bay Campus,, San Francisco, California, 94158, USA.
2: Department of Bioengineering and Therapeutic Sciences, 1700 4th Street Room 204, UCSF Mission Bay Campus,, San Francisco, California, 94158, USA.
3: Women's Global Health Imperative, RTI International, 351 California Street,, San Francisco, California, 94104, USA.
4: Emerging Technologies, Research Triangle Institute (RTI) International, Research Triangle Park, North Carolina, 27709, USA.
5: University of Pittsburgh Medical School, 204 Craft Ave Rm B-621, Pittsburgh, Pennsylvania, 15213, USA.
6: Center for AIDS Prevention Studies (CAPS), Department of Medicine, UCSF Mission Bay Campus,, San Francisco, California, 94158, USA.
7: UC Berkeley-UCSF Graduate Program in Bioengineering, 1700 4th Street Room 204, UCSF Mission Bay Campus,, San Francisco, California, 94158, USA. tejal.desai@ucsf.edu.
8: Department of Bioengineering and Therapeutic Sciences, 1700 4th Street Room 204, UCSF Mission Bay Campus,, San Francisco, California, 94158, USA. tejal.desai@ucsf.edu.

Associated clinical trials:

Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women | NCT02357602

Articles cited by this

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84

Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28

Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20

Stopping antiretroviral therapy. AIDS (2007) 2.63

Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav (2013) 2.03

The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials (2005) 2.01

Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS (2013) 1.73

Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother (2005) 1.63

Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis. Annu Rev Med (2012) 1.36

Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother (2010) 1.35

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr (2013) 1.31

Modeling of diffusion controlled drug delivery. J Control Release (2011) 1.20

GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr (2014) 1.07

Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob Agents Chemother (2015) 0.99

Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm (2012) 0.98

An overview of antiretroviral pre-exposure prophylaxis of HIV infection. Am J Reprod Immunol (2014) 0.87

Polycaprolactone thin-film drug delivery systems: Empirical and predictive models for device design. Mater Sci Eng C Mater Biol Appl (2015) 0.84

In Vitro and In Vivo Sustained Zero-Order Delivery of Rapamycin (Sirolimus) From a Biodegradable Intraocular Device. Invest Ophthalmol Vis Sci (2015) 0.83

Editorial Commentary: Unmasking the Bare Bones of HIV Preexposure Prophylaxis. Clin Infect Dis (2015) 0.79